Natco Pharma on Monday said it has received approval from the USFDA to market Lanthanum Carbonate chewable tablets used in the treatment of patients with end-stage renal disease. Its first generic product will be launched in the US soon. Fosrenol tablets had sales of $122.4 million during June 2017 in the US.
Natco and Lupin had entered into a pact in 2008 to jointly commercialise the generic equivalents of Fosrenol chewable tablets.